# Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

> **NCT02717962** · PHASE2 · COMPLETED · sponsor: **Kintara Therapeutics, Inc.** · enrollment: 118 (actual)

## Conditions studied

- Glioma
- Glioblastoma
- Glioblastoma Multiforme
- GBM
- Brain Cancer

## Interventions

- **DRUG:** VAL-083, Dianhydrogalactitol

## Key facts

- **NCT ID:** NCT02717962
- **Lead sponsor:** Kintara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-20
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717962, "Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02717962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*